Severe androgenetic alopecia as a maker of metabolic syndrome in male patients of androgenetic alopecia: a hospital based case control study


  • Mohd. R. Tilwani Department of Dermatology, Government Medical College Jammu, Jammu, Jammu and Kashmir, India
  • Naina K. Dogra Department of Dermatology, Government Medical College Jammu, Jammu, Jammu and Kashmir, India
  • Devraj Dogra Department of Dermatology, Government Medical College Jammu, Jammu, Jammu and Kashmir, India
  • Suhail Raheem Rather Department of Dermatology, SKIMS Medical College & Hospital, Srinagar, Jammu and Kashmir, India
  • Parvaiz A. Rather Department of Dermatology, Government Medical College Jammu, Jammu, Jammu and Kashmir, India



Androgenetic alopecia, Cardiovascular disease, Metabolic syndrome


Background: Several previous studies have investigated the association between androgenetic alopecia (AGA) and metabolic syndrome (MS), with inconsistent results. Objectives of the study were to study the prevalence of metabolic syndrome in male patients of androgenetic alopecia and compare with control population and study the relationship of metabolic syndrome with different grades of AGA.

Methods: This prospective hospital based case control study included 100 new clinically diagnosed males of androgenetic alopecia, and age and sex matched control group. Assessment for presence of various components of metabolic syndrome was done following a uniform protocol in cases and controls. AGA was classified as per Hamilton –Narwood classification, grade I to III was classified as mild –moderate and grade IV and higher as severe AGA.

Results: Of the 100 male AGA patients (age range 21-50, mean 34.49), 36 had grade II AGA, 24 had grade III AGA, 20 had grade IV AGA, 15 had grade V AGA and 5 had grade VI AGA. Among AGA patients, 60 of patients had mild-moderate AGA and 40 patients had severe AGA. Metabolic syndrome was statistically significantly more common in patients with AGA compared to controls. Among patients of AGA, metabolic syndrome was statistically significantly present in severe AGA compared to mild-moderate AGA. Among the evaluated parameters, like blood pressure, fasting blood sugar, dyslipedemia, abdominal obesity, all were significantly more common in AGA patients compared to controls except abdominal obesity.

Conclusions: In the present study, metabolic syndrome was found to be 4.6 times more common in patients of androgenetic alopecia as compared to controls, being statistically significant, and more common in those with severe grades. This suggests that androgenetic alopecia patients especially with severe grades are at risk of metabolic syndrome and other cardiovascular diseases.


Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37:981-90.

Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for androgenetic alopecia. J Am Acad Dermatol. 1996;35:465-9.

Paus R, Cotsaralis G. The biology of hair follicles. N Eng J Med. 1999;341:491-7.

Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male baldness. J Invest Dermatol. 2005;121:1561-4.

Robera A. Pathogenesis of androgenetic alopecia. J Am Acad Dermatol. 2004;50:777-9.

Millar SE. Molecular mechanisms regulating hair follicle development. J Invest Dermatol. 2012;118:216-25.

Kitagawa T, Matsuda K, Inui S, Takenaka H, Katoh N, Itami S, et al. Keratinocyte growth inhibition through the modification of wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab. 2009;94:1288-94.

Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010;63:420-9.

Langen SM. Prevalence of metabolic syndrome in male patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132:556-62.

Narwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359-65.

Cotton SG, Nixon JM, Evans DW. Factors discriminating men with coronary heart disease from healthy controls. Br Heart J. 1972;34:458-64.

Grover S. A study of patterns of androgenetic alopecia in men: An Indian perspective. Br J Dermatol. 2005;152:572-4.

Sehgal VN, Kak R, Aggarwal A, Srivastava G, Rajput P. Male pattern androgenetic alopecia in an indian context: A perspective study. J Eur Acad Dermatol Venereol. 2007;21:473-9.

Banger HS, Malhotra SK, Mahajan M. Is early onset androgenic alopecia a marker of metabolic syndrome and carotid artery atherosclerosis in young Indian male patients? Int J Trichol. 2015;7:141-7.

Acibucu F, Kayatas M, Canadan F. The association of insulin resistance and metabolic syndrome in early androgenetic alopecia. Singapore Med J. 2010;51:931-6.

Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: A community based survey. Br J Dermatol. 2010;163:371-7.

Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011;21:79-82.

Gok SO, Belli AK, Dervis E. Is there really relationship between androgenetic alopecia and metabolic syndrome? Dermatol research and pract. 2015;9:80310-14.

Bakry OA, Shoeib MA, El Shafiee MK, Hassan A. Androgenetic alopecia, metabolic syndrome, and insulin resistance: Is there any association? A case-control study. Indian dermatol online J. 2014;5:276-81.

Hirsso P, Laakso M, Matilainen V, Hiltunen L, Rajala U, Jokelainen J, et al. Association of insulin resistance-linked diseases and hair loss in elderly men. Finnish population –based study. Cent Eur J Public Health. 2006;14:78-81.

Fatma M, Rahman SH. Androgenetic alopecia as an early markerfor hypertension. Egypt J Dermatol Venerol. 2013;33:63-6.

Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol. 2007;17:220-2.

Hirsso P, Rajala U, Hiltunen L, Jokelainen J, Keinänen-Kiukaanniemi S, Näyhä S. Obesity and low grade inflammation among young Finnish men with early-onset alopecia. Dermatology. 2007;214:125-9.

Spinler SA. Challenges associated with metabolic syndrome. Pharmacotherapy. 2006;26(12pt 2):209S-17S.

Sasmaz S, Senol M, Ozcan A, Dogan G, Tuncer C, Akyol O, et al. Risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol. 1999;12:123-5.

Guzzo CA, Margolis DJ, Johnson J. lipid profiles, alopecia, and coronary disease: Any relationship? Dermatol surg. 1996;22:481.

Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid lowering goals. Am J cardiol. 2003;91:11C-17C.

Sharrett AR, Sorlie PD, Chambless LE, Folsom AR, Hutchinson RG, Heiss G, et al. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: The atherosclerosis risk in communities study. Am J Epidemiol. 1999;149:843-52.

Nabaie L, Kavand S, Robati RM, Sarrafi-Rad N, Kavand S, Shahgholi L, et al. Androgenic alopecia insulin resistance. Are they really related? Clin Exp Dermatol. 2009;34:694-7.




How to Cite

Tilwani, M. R., Dogra, N. K., Dogra, D., Rather, S. R., & Rather, P. A. (2017). Severe androgenetic alopecia as a maker of metabolic syndrome in male patients of androgenetic alopecia: a hospital based case control study. International Journal of Research in Medical Sciences, 5(2), 601–606.



Original Research Articles